News | Radiation Therapy | April 01, 2016

Pyrexar Announces New Partnership to Bring Hyperthermia Cancer Therapy to Cuba

Distribution network will include Cuba, the West Indies, Panama and Venezuela

Pyrexar Medical, hyperthermia products, Cuba, West Indies, Clinitech Co. Ltd.

April 1, 2016 — Pyrexar Medical announced a new distribution partnership with Clinitech Co. Ltd., bringing Pyrexar’s hyperthermia technologies into Cuba, the West Indies, Panama and Venezuela.

Cancer deaths are high in Cuba at 138 per 100,000, according to World Life, an organization that tracks death causality throughout the world. Cuba cancer stats rank 31 in the world, slightly lower than the United Kingdom, and several points higher than the United States. According to a study in 2001-2003 by the National Cancer Registry, lung, prostate, throat and colon cancers had high incidence in men, while breast, cervix, lung and colon cancers were the most prevalent in women.

Clinitech will be providing sales and service for the Pyrexar family of superficial, interstitial and deep regional hyperthermia devices. Leading their team is Ross University School of Medicine Oncology Professor Kamal Malaker, M.D., Ph.D., who has successfully used hyperthermia technology in the treatment of cancer. “We are excited to bring this relatively under-explored, under-utilized, well-proven, life-saving technology to the region.” said Wazir Mohammed, Clinitech’s president.

The distribution territory includes: Antigua, Aruba, Bahamas, Barbados, Belize, Bermuda, Bonaire, British Virgin Islands, Cayman Islands, Cuba, Curacao, Dominica, Dominican Republic, Grenada, Guyana, Haiti, Jamaica, Montserrat, Panama, Puerto Rico, Saba, St. Ecstasies, St Kitts & Nevis, St. Lucia, St. Maarten, St. Vincent. Suriname, Trinidad and Tobago, Turks and Caicos, U.S. Virgin Islands (St. Thomas, St. Croix and St John) and Venezuela.

For more information:

Related Content

Videos | Radiation Therapy | February 21, 2019
ITN Associate Editor Jeff Zagoudis speaks with Christy Kesslering, M.D., medical director of radiation oncology at th
FDA Clears Advancements for Viewray MRIdian Radiation Therapy System
Technology | Image Guided Radiation Therapy (IGRT) | February 21, 2019
February 21, 2019 — ViewRay Inc. received 510(k) clearance from the U.S.
Videos | Radiation Therapy | February 20, 2019
ITN Associate Editor Jeff Zagoudis speaks with Vinai Gondi, M.D., director of research and CNS neuro-oncology at the
Study Unveils Blueprint for Treating Radiation-Resistant Brain Tumor

NIH-funded researchers showed how gliomas may be treated with radiation and drugs that block DNA repair. Image courtesy of Castro lab, Michigan Medicine, Ann Arbor


News | Radiation Therapy | February 19, 2019
February 19, 2019 — Researchers at the University of Michigan recently searched for new brain tumor treatments by exp
Videos | Radiation Therapy | February 15, 2019
ITN Associate Editor Jeff Zagoudis speaks with Vinai Gondi, M.D., director of research and CNS neuro-oncology at the
New Targeted Therapy for Recurrent Brain Tumors Implanted for First Time
News | Radiation Therapy | February 15, 2019
University of Minnesota Health (M Health) is the first in the United States to begin offering GammaTile Therapy, a new...
Canon Adds Radiation Therapy Package to Aquilion Prime, Lightning CT Systems
News | Computed Tomography (CT) | February 11, 2019
In the patient-centric world of radiation oncology, it is critical that computed tomography (CT) simulation is...
Elekta Unity MR-Linac Earns FDA Clearance
Technology | Image Guided Radiation Therapy (IGRT) | February 07, 2019
The Elekta Unity magnetic resonance radiation therapy (MR/RT) system recently received 510(k) premarket notification...
University of Oklahoma Cancer Center Begins First Proton Therapy Treatments
News | Proton Therapy | February 01, 2019
Home to the largest and most comprehensive radiation therapy program in Oklahoma, the Stephenson Cancer Center at OU (...
Stereotactic Radiotherapy Improves Long-Term Survival in Stage-IV Cancers
News | Stereotactic Body Radiation Therapy (SBRT) | January 31, 2019
The first report from a phase II, multi-center clinical trial indicates stereotactic radiation can extend long-term...